Purpose: The study is to determine the impact of debt policy on the IDX listed pharma dividend policy, liquidity impact on the IDX listed pharma dividend policy, and profitability impact on the IDX listed pharma dividend policy. The impact of debt policy, liquidity and profitability on the dividend policy of pharmaceutical companies concurrently or partially listed on the IDX. Methodology: This study uses quantitative methods and secondary data. The scope of this research relates to data on manufacturing companies listed on the Indonesia Stock Exchange in 2017 - 2020. Results: Results: The results of multiple linear regression analysis show that debt, liquidity, and profitability policies have an effect on dividend policy on the Indonesia Stock Exchange. On the other hand, some profitability has a negative effect on dividend policy. However, debt and liquidity policies have a partial positive effect on dividend policy. Limitations: Only tested 3 factor variables that affect dividen policy in a certain period. Contribution: It is hoped that this research can be useful for investors who will invest in certain pharmaceutical business sectors to be more careful in paying attention to various factors that affect stock returns. Keywords: 1. Debt 2. Liquidity 3. Profitability 4. Dividend Policy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.